Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | GSR | P00390 | 2/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL780498 | 0.87 | NPC1 (0.63) | NPC1RAB9AL3MBTL1RECQLHSD11B1 | |
| SCHEMBL7619212 | 0.87 | SRD5A2 (0.56) | NPC1RAB9AL3MBTL1GSRAKR1C3 | |
| SCHEMBL5218244 | 0.86 | NPC1 (0.81) | NPC1RAB9AL3MBTL1KMT2ALMNA | |
| SCHEMBL6970870 | 0.85 | PTGS2 (0.53) | GSRPTGS2AKR1C3KMT2APAX8 | |
| SCHEMBL4772305 | 0.85 | PTGS2 (0.53) | GSRPTGS2AKR1C3KMT2APAX8 | |
| SCHEMBL6168486 | 0.85 | CA1 (0.62) | NPC1RAB9AL3MBTL1KMT2A | |
| SCHEMBL8602859 | 0.85 | MAPT (0.59) | L3MBTL1GSRPTGS2AKR1C3LMNA | |
| SCHEMBL6341279 | 0.85 | PTGS2 (0.51) | L3MBTL1GSRPTGS2RECQL | |
| SCHEMBL7625358 | 0.83 | CA12 (0.52) | NPC1RAB9AGSRPTGS2KMT2A | |
| SCHEMBL9028776 | 0.83 | CA12 (0.52) | NPC1RAB9AGSRPTGS2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919353-B2 | Substituted 8-arylquinolune PDE4 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2005-07-19 | — | — | US | disclosed |
| EP-1404330-B1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-06-01 | — | — | EP | disclosed |
| US-20040162314-A1 | Substituted 8-arylquinolune pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2004-08-19 | — | — | US | disclosed |
| EP-1404330-A1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003002118-A1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002118-A1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162314-A1 | Substituted 8-arylquinolune pde4 inhibitors | PDE12, PDE4A, PDE4B | NPC1 2515/4885RAB9A 536/4885L3MBTL1 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.